ArticleScience advances2025
Enhanced
Abstract read
In one paragraph
Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Engineered dCas12f1-SAM enables robust transcriptional activation and gain-of-function screening in primary human cells.Nature communications · 2026Article
- Functional Type I and Type II interferon crosstalk restricts progenitor exhausted CD8 T cells through spatial exclusion and checkpoint enforcement.bioRxiv : the preprint server for biology · 2026Article
- Reversible control of T cell exhaustion by NR4A transcription factors revealed through targeted protein degradation.bioRxiv : the preprint server for biology · 2026Article
- Current Status and Evolution of Immunotherapy in Glioma Management.International journal of medical sciences · 2026Review
- The trinity of T cell engagement: navigating the molecular and clinical landscape of CAR-T, TILs, and TCEs in the war against cancer.Frontiers in immunology · 2026Review
- Organoid models: reshaping the paradigm for precision development and evaluation of CAR-T cell therapies.Frontiers in bioengineering and biotechnology · 2026Review
- Targeting innate immunity to overcome immune evasion in HPV-associated cancers.Frontiers in cellular and infection microbiology · 2026Review
- Terminally exhausted CD8Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Peidi YinDepartment of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, P.R. China.ORCID 0000-0002-7172-7560
Jigui YangInstitute of Pathology, Medical Research Center for Glioma, Southwest Cancer Center, the First Affiliated Hospital (Southwest Hospital) and School of Basic Medical Sciences, Army Medical University (Third Military Medical University), and the Key Laboratory of Tumor Immunopathology, the Ministry of Education (Third Military Medical University), Chongqing 400038, China.ORCID 0000-0003-1421-8193
Yiyang JiangDepartment of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, P.R. China.ORCID 0009-0001-5026-419X
Linhong HanInstitute of Pathology, Medical Research Center for Glioma, Southwest Cancer Center, the First Affiliated Hospital (Southwest Hospital) and School of Basic Medical Sciences, Army Medical University (Third Military Medical University), and the Key Laboratory of Tumor Immunopathology, the Ministry of Education (Third Military Medical University), Chongqing 400038, China.
Tianchen XiongDepartment of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, CA 91010, USA.ORCID 0009-0003-8131-3550
Haofei LiuInstitute of Pathology, Medical Research Center for Glioma, Southwest Cancer Center, the First Affiliated Hospital (Southwest Hospital) and School of Basic Medical Sciences, Army Medical University (Third Military Medical University), and the Key Laboratory of Tumor Immunopathology, the Ministry of Education (Third Military Medical University), Chongqing 400038, China.ORCID 0000-0002-4584-3103
Yiliang FangInstitute of Pathology, Medical Research Center for Glioma, Southwest Cancer Center, the First Affiliated Hospital (Southwest Hospital) and School of Basic Medical Sciences, Army Medical University (Third Military Medical University), and the Key Laboratory of Tumor Immunopathology, the Ministry of Education (Third Military Medical University), Chongqing 400038, China.ORCID 0000-0003-2414-2532
Wenchen RuanInstitute of Pathology, Medical Research Center for Glioma, Southwest Cancer Center, the First Affiliated Hospital (Southwest Hospital) and School of Basic Medical Sciences, Army Medical University (Third Military Medical University), and the Key Laboratory of Tumor Immunopathology, the Ministry of Education (Third Military Medical University), Chongqing 400038, China.
Jiayang WuInstitute of Pathology, Medical Research Center for Glioma, Southwest Cancer Center, the First Affiliated Hospital (Southwest Hospital) and School of Basic Medical Sciences, Army Medical University (Third Military Medical University), and the Key Laboratory of Tumor Immunopathology, the Ministry of Education (Third Military Medical University), Chongqing 400038, China.ORCID 0000-0003-2900-7399
Longjuan ChenInstitute of Pathology, Medical Research Center for Glioma, Southwest Cancer Center, the First Affiliated Hospital (Southwest Hospital) and School of Basic Medical Sciences, Army Medical University (Third Military Medical University), and the Key Laboratory of Tumor Immunopathology, the Ministry of Education (Third Military Medical University), Chongqing 400038, China.
Leyong TanInstitute of Pathology, Medical Research Center for Glioma, Southwest Cancer Center, the First Affiliated Hospital (Southwest Hospital) and School of Basic Medical Sciences, Army Medical University (Third Military Medical University), and the Key Laboratory of Tumor Immunopathology, the Ministry of Education (Third Military Medical University), Chongqing 400038, China.
Yonglin ZuoInstitute of Pathology, Medical Research Center for Glioma, Southwest Cancer Center, the First Affiliated Hospital (Southwest Hospital) and School of Basic Medical Sciences, Army Medical University (Third Military Medical University), and the Key Laboratory of Tumor Immunopathology, the Ministry of Education (Third Military Medical University), Chongqing 400038, China.
Xin WuInstitute of Pathology, Medical Research Center for Glioma, Southwest Cancer Center, the First Affiliated Hospital (Southwest Hospital) and School of Basic Medical Sciences, Army Medical University (Third Military Medical University), and the Key Laboratory of Tumor Immunopathology, the Ministry of Education (Third Military Medical University), Chongqing 400038, China.ORCID 0000-0002-0767-0141
Fangyuan MaoInstitute of Pathology, Medical Research Center for Glioma, Southwest Cancer Center, the First Affiliated Hospital (Southwest Hospital) and School of Basic Medical Sciences, Army Medical University (Third Military Medical University), and the Key Laboratory of Tumor Immunopathology, the Ministry of Education (Third Military Medical University), Chongqing 400038, China.
Rui HuangInstitute of Pathology, Medical Research Center for Glioma, Southwest Cancer Center, the First Affiliated Hospital (Southwest Hospital) and School of Basic Medical Sciences, Army Medical University (Third Military Medical University), and the Key Laboratory of Tumor Immunopathology, the Ministry of Education (Third Military Medical University), Chongqing 400038, China.
Xindong LiuInstitute of Pathology, Medical Research Center for Glioma, Southwest Cancer Center, the First Affiliated Hospital (Southwest Hospital) and School of Basic Medical Sciences, Army Medical University (Third Military Medical University), and the Key Laboratory of Tumor Immunopathology, the Ministry of Education (Third Military Medical University), Chongqing 400038, China.ORCID 0000-0002-2465-0337
Xiu-Wu BianDepartment of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, P.R. China.ORCID 0000-0003-4383-0197
Funding
No grant is acknowledged in the PubMed record.
Abstract
The dysfunction of chimeric antigen receptor (CAR) T cells in the tumor microenvironment is a major obstacle to their therapeutic efficacy against solid tumors. Through single-cell RNA sequencing analysis of tumor-infiltrating T cells from patients with glioma, NR4A family genes were identified as closely associated with T cell exhaustion and were coexpressed with dysfunctional genes
Indexed as
GliomaImmunotherapy, AdoptiveReceptors, Chimeric AntigenReceptors, SteroidReceptors, Thyroid HormoneT-LymphocytesAnimalsCell Line, TumorDNA-Binding ProteinsGene Expression Regulation, NeoplasticHumansMiceTumor MicroenvironmentDNA-Binding ProteinsNR4A3 protein, humanReceptors, Chimeric AntigenReceptors, SteroidReceptors, Thyroid Hormone
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.